{
    "pmcid": "8248807",
    "qa_pairs": {
        "What is a significant challenge in the development of antibodies and nanobodies against SARS-CoV-2?": [
            "Overcoming viral mutations that may affect binding efficacy",
            "Ensuring antibodies can penetrate the viral envelope",
            "Producing antibodies that can target multiple viruses simultaneously",
            "Developing antibodies that can be administered orally"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein as described in the paper?": [
            "Facilitating viral entry by binding to the host cell receptor ACE2",
            "Providing structural support to the viral envelope",
            "Acting as an enzyme to replicate viral RNA",
            "Serving as a decoy to evade the host immune system"
        ],
        "What is the role of the S1 subunit of the SARS-CoV-2 spike protein?": [
            "Contains the receptor-binding domain (RBD) critical for ACE2 recognition",
            "Involved in membrane fusion during viral entry",
            "Acts as a scaffold for the S2 subunit",
            "Facilitates viral assembly within the host cell"
        ],
        "Which mutation in the SARS-CoV-2 spike protein is associated with increased infectivity and transmission?": [
            "D614G mutation",
            "N501Y mutation",
            "E484K mutation",
            "K417N mutation"
        ],
        "Which therapeutic agents are mentioned as having high affinity for the RBD of the SARS-CoV-2 spike protein?": [
            "De novo designed mini proteins LCB1 and LCB3",
            "Antiviral drugs like Remdesivir",
            "Traditional vaccines targeting the whole virus",
            "Interferon-based therapies"
        ]
    }
}